1. Ocular Pharmacokinetics and Pharmacodynamics in Rabbits of Ibopamine, a New Mydriatic Agent
- Author
-
Isabella Galbiati, Luciano Soldati, M. Virno, Valter Gianesello, and Annibale Gazzaniga
- Subjects
Male ,Mydriatics ,Bunazosin ,Reserpine ,Time Factors ,Swine ,Pharmacology ,Dopamine agonist ,Aqueous Humor ,Cellular and Molecular Neuroscience ,Pharmacokinetics ,Cornea ,Ibopamine ,medicine ,Mydriasis ,Animals ,Dose-Response Relationship, Drug ,Chemistry ,Pupil ,Sensory Systems ,Deoxyepinephrine ,Ophthalmology ,medicine.anatomical_structure ,Moxisylyte ,Pharmacodynamics ,Quinazolines ,Female ,Rabbits ,medicine.symptom ,Adrenergic alpha-Agonists ,medicine.drug - Abstract
Ibopamine is an original dopamine analogue. The drug, instilled in the conjunctival sac, induces mydriasis and is well-tolerated. In the present study, we have investigated the pharmacokinetic and pharmacodynamic characteristics of ibopamine alter ocular application. Ibopamine produces a dose-dependent mydriasis endowed with very interesting characteristics: rapid onset, marked pupil dilation and rapid return to normal pupillary diameter. Ibopamine is well absorbed through the cornea, it is rapidly hydrolysed by esterases to epinine and the mydriatic effect is correlated with the concentration of epinine in the aqueous humor. The results of the experiments with the α1-antagonists bunazosin and thymoxamine, and with reserpine, suggest that the mydriatic effect of ibopamine is obtained by direct stimulation of the α1-adrenergic receptors; pretreatment with bunazosin almost completely inhibits the mydriatic activity of ibopamine: the mydriasis is also antagonized by thymoxamine. Pretreatment with reserpine has no effect on the extent of the mydriasis induced by ibopamine.
- Published
- 1993
- Full Text
- View/download PDF